IntelGenx (TSXV:IGX; OTCQX:IGXT) announced plans to add a new Ottawa site to its Montelukast VersaFilm Phase 2a clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD).
“While we are not able to identify it until final Research Ethics Board approval is obtained, we are looking forward to patient recruitment starting at this site in the near future,” Dr. Horst Zerbe, CEO of IntelGenx, said in a statement.
The Phase 2a proof-of-concept study expects to enroll about 70 subjects with mild-to-moderate AD. The study will evaluate the safety, feasibility, tolerability, and efficacy of montelukast buccal film following daily dosing for 26 weeks.
To-date, the study has enrolled 23 subjects. IntelGenx also said that the study has now completed 26-week treatment of its first subject.
